INDIAGLYCO2024-01-012024-03-31 INDIAGLYCO2024-01-012024-03-31 INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneOperatingExpenses03Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourOperatingExpenses03Member INDIAGLYCO2024-03-31 INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue03Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue03Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults03Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults03Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets03Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member INDIAGLYCO2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member INDIAGLYCO2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member INDIAGLYCO2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member INDIAGLYCO2024-03-31in-bse-fin:OneReportableSegmentLiabilities03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500201 INDIAGLYCO NOTLISTED India Glycols Limited Equity 2023-04-01 2024-03-31 2024-05-28 2024-05-21 INR Crores Yearly 15:45:00 17:06:00 2024-05-28 2024-05-28 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Audited Consolidated 20390800000.00 46500000.00 20437300000.00 5014600000.00 1156900000.00 186100000.00 299400000.00 326300000.00 260400000.00 12688000000.00 19931700000.00 505600000.00 0.00 505600000.00 12200000.00 121700000.00 133900000.00 0.00 371700000.00 0.00 0.00 0.00 50400000.00 422100000.00 -1400000.00 420700000.00 422100000.00 0.00 420700000.00 0.00 309600000.00 10 13.63 13.63 0.00 0.00 13.63 13.63 Note on Financial Results: At point no.26 'Face value of equity share capital' of Rs.10 is the Face value per equity share. Note on Cash Flow Statement: (1) Since there is no option to fill ‘adjustment for (Profit)/Loss on Sale of Property, plant & equipment’, 'Govt. Grants' and ‘Provision No Longer Required Written Back’ in the utility, the same are shown in 'Other adjustment for non-cash items'. The actual figures (Rs. in crore) are as follows: (a) Adjustment for (Profit)/Loss on Sale of Property, plant & equipment: -3.89 (b) Provision No Longer Required Written Back: -0.19 (c) Govt. Grants: -0.12 Multi segment 2023-04-01 2024-03-31 Audited Consolidated 79215400000.00 257300000.00 79472700000.00 18189200000.00 3218000000.00 81100000.00 1033700000.00 1206700000.00 1007700000.00 52669800000.00 77406200000.00 2066500000.00 0.00 2066500000.00 109000000.00 394200000.00 503200000.00 0.00 1563300000.00 0.00 0.00 0.00 166600000.00 1729900000.00 -1900000.00 1728000000.00 1729900000.00 0.00 1728000000.00 0.00 309600000.00 10 0.00 55.87 55.87 0.00 0.00 55.87 55.87 Excise Duty 11129400000.00 Other Expenses 836200000.00 Power and Fuel 722400000.00 Excise Duty 46275700000.00 Other Expenses 3109700000.00 Power and Fuel 3284400000.00 0.00 31967700000.00 835500000.00 65600000.00 0.00 16300000.00 0.00 0.00 0.00 3351400000.00 0.00 5400000.00 425200000.00 3782000000.00 0.00 53900000.00 36721000000.00 11062900000.00 0.00 3841000000.00 269600000.00 1108700000.00 0.00 1272100000.00 6491400000.00 62600000.00 1830100000.00 19447000000.00 0.00 0.00 56168000000.00 309600000.00 20200600000.00 20510200000.00 20510200000.00 7250800000.00 0.00 597500000.00 7848300000.00 48500000.00 3984100000.00 0.00 29600000.00 11910500000.00 5960300000.00 10994500000.00 3820000000.00 20774800000.00 2945100000.00 27400000.00 0.00 0.00 23747300000.00 0.00 0.00 35657800000.00 56168000000.00 Note1: Since there is no option to fill 'Right to use assets' in the utility, the same is clubbed with 'Property, Plant and Equipment'. The actual figures (Rs. in crore) are as follows: (a) Property, Plant and Equipment: 3171.29 (b) Right to use assets: 25.48 Note2: Since there is no option to fill 'Lease Liabilities' in the utility, the same is clubbed with 'Other financial liabilities'. Bio-based Specialities and Performance Chemicals 6231600000.00 Ennature Biopharma 556700000.00 Potable Spirits 13602500000.00 Bio-based Specialities and Performance Chemicals 21414800000.00 Ennature Biopharma 2051500000.00 Potable Spirits 55749100000.00 20390800000.00 79215400000.00 0.00 0.00 20390800000.00 79215400000.00 Bio-based Specialities and Performance Chemicals 472200000.00 Ennature Biopharma 69300000.00 Potable Spirits 399800000.00 Bio-based Specialities and Performance Chemicals 1681100000.00 Ennature Biopharma 386000000.00 Potable Spirits 1642300000.00 941300000.00 3709400000.00 326300000.00 1206700000.00 59000000.00 Note for Segment results: Since there is no option to fill 'Share of profit/ (loss) of Joint Venture' in the utility, the same is clubbed with 'Other unallocable Expenditure net off Unallocable income'. The actual figures (Rs. in Crore) are as follows: for Q4FY24: (a) Other unallocable Expenditure net off Unallocable income: 10.94 (b) Share of profit/ (loss) of Joint Venture: 5.04 for FY24: (a) Other unallocable Expenditure net off Unallocable income: 43.62 (b) Share of profit/ (loss) of Joint Venture: 16.66 269600000.00 556000000.00 2233100000.00 Bio-based Specialities and Performance Chemicals 41640100000.00 Ennature Biopharma 4271800000.00 Potable Spirits 4663800000.00 50575700000.00 5592300000.00 56168000000.00 Bio-based Specialities and Performance Chemicals 13433200000.00 Ennature Biopharma 928800000.00 Potable Spirits 3972700000.00 18334700000.00 17323100000.00 35657800000.00 1234800000.00 -3524500000.00 620400000.00 0.00 0.00 0.00 0.00 0.00 0.00 3246700000.00 0.00 0.00 0.00 1007700000.00 0.00 52200000.00 0.00 0.00 0.00 69900000.00 0.00 235800000.00 0.00 0.00 0.00 0.00 -1800000.00 -42000000.00 0.00 2427600000.00 4494100000.00 0.00 0.00 0.00 109000000.00 0.00 4385100000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 109200000.00 5529300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 383800000.00 0.00 1800000.00 0.00 -5034500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4633100000.00 2364700000.00 0.00 -89200000.00 229700000.00 1228600000.00 0.00 0.00 899300000.00 249900000.00 0.00 249900000.00 19700000.00 269600000.00 -600000.00 2600000.00 -100000.00 700000.00 900000.00 3800000.00